Early Age-Related Hearing Loss Investigation (EARHLI): A Randomized Controlled Trial to Assess Mechanisms Linking Early Age-Related Hearing Loss and Alzheimer's Disease and Related Dementias
早期年龄相关性听力损失调查 (EARHLI):一项随机对照试验,旨在评估早期年龄相关性听力损失与阿尔茨海默病和相关痴呆症之间的联系机制
基本信息
- 批准号:10521559
- 负责人:
- 金额:$ 107.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdherenceAgeAge-associated memory impairmentAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAlzheimer&aposs disease riskAmyloidAuditoryAuditory areaBehavioralBrainChronicClinical TrialsCognitionCognitiveComparison armDataDementiaDevelopmentDevicesDiagnosisDiseaseElderlyFunctional Magnetic Resonance ImagingGenotypeGoalsHealth educationHearingHearing AidsHourImpaired cognitionIndividualInterventionInvestigationKnowledgeLinkMagnetic Resonance ImagingMeasuresMediatingNeuropsychologyOutcomeParticipantPathologicPathway interactionsPerformancePersonsPhasePhase I Clinical TrialsPlasmaPresbycusisPreventionPublic HealthPure-Tone AudiometryRandomized Controlled TrialsReportingRestRiskRisk FactorsSiteSocial ChangeTarget PopulationsTestingTimeVisualamnestic mild cognitive impairmentarmbasecognitive functioncognitive loadcognitive performancecognitive testingcooperative studydiffusion weighteddigitalefficacy testinghearing impairmentimprovedinterestintervention effectmild cognitive impairmentmultidisciplinarypreclinical studypreventprogramsresponsesexsocialsocial engagementtreatment arm
项目摘要
PROJECT SUMMARY/ABSTRACT
This proposal is an early phase II randomized controlled trial (RCT) to obtain preliminary data on mechanisms
and efficacy of a hearing aid-based intervention to prevent cognitive decline in those at risk for Alzheimer’s
Disease and Alzheimer’s Disease Related Dementias (AD/ADRD). The target risk group is 55-75-year old people
with early-stage age-related hearing loss (ARHL) and amnestic mild cognitive impairment. The RCT, entitled
“Early Age-Related Hearing Loss Investigation (EARHLI)” is in response to PAR-18-877, “Early Stage Clinical
Trials for the Spectrum of Alzheimer’s Disease and Age-related Cognitive Decline.” ARHL, the third most
common chronic condition in later life, is associated with cognitive impairment/AD/ADRD. This finding has
recently been extended to early ARHL (borderline-to-moderate hearing loss [20-55 dB] on pure tone audiometry),
which is rarely treated with hearing aids. The mechanisms linking ARHL and AD/ADRD are unknown, but
reduced social engagement and changes in brain organization/connectivity have been proposed. A 2020 Lancet
Commissions report estimated that eliminating ARHL could be associated with an 8% reduction in new dementia
cases, at least as much as well-established risk factors. Yet, 90% of the target population is not treated with
hearing aids and there is a dearth of RCTs testing the efficacy of hearing aids in ARHL. While studies have
suggested hearing aids improve social engagement, brain organization/connectivity, and, in turn, cognition, there
is no RCT evidence supporting these observations. There is one ongoing RCT (ACHIEVE, ClinicalTrials.gov
NCT03243422) examining the effect of a hearing intervention on cognition in older adults with more advanced
ARHL. EARHLI focuses on early ARHL in middle and early older age, a critical time for AD/ADRD prevention.
Unlike ACHIEVE, EARHLI also measures brain organization/connectivity. EARHLI will be a phase II 1:1 RCT of
a hearing aid-based intervention versus a comparator (health education program) conducted over 12 months in
150 participants (n=76 undergoing MRI) with early ARHL at risk for AD/ADRD. The overarching hypothesis is
that the hearing intervention will lead to improved social engagement and brain organization/connectivity that
will lead to improved cognition compared with the comparator arm. This hypothesis will be tested with an intent-
to-treat approach comparing the hearing intervention and comparator arms. Aim 1 is to compare change in
cognitive performance measured with the Alzheimer’s Disease Cooperative Study Preclinical Alzheimer
Cognitive Composite (ADCS-PACC; 1º outcome) and by domain-specific cognitive testing on ADCS-PACC
components (0, 6, 12 months). Aim 2 is to compare change in social engagement measured by activity
participation (1º outcome) and network size/support (at 0, 6, 12 months). Aim 3 is to compare changes in brain
organization/connectivity using task (visual task, auditory regions of interest,1º outcome) and resting-state fMRI,
and diffusion-weighted structural connectivity (at 0, 12 months). We will explore whether social engagement and
brain organization/connectivity mediate the effects of the intervention on cognitive outcomes.
项目总结/摘要
这一建议是一个早期的II期随机对照试验(RCT),以获得机制的初步数据
以及基于助听器的干预措施预防阿尔茨海默病风险人群认知能力下降的有效性
阿尔茨海默病相关性痴呆(AD/ADRD)。目标风险人群为55-75岁的老年人
早期年龄相关性听力损失(ARHL)和遗忘性轻度认知障碍。该RCT题为
“早期听力损失相关调查(EARHLI)”是对PAR-18-877“早期临床
老年痴呆症和阿尔茨海默氏症相关认知能力下降的试验。ARHL,第三大
老年常见慢性病,与认知障碍/AD/ADRD相关。这一发现
最近扩展到早期ARHL(纯音测听的边缘至中度听力损失[20-55 dB]),
很少用助听器治疗。ARHL和AD/ADRD之间的联系机制尚不清楚,
已经提出了减少的社会参与和大脑组织/连接的变化。2020年柳叶刀
委员会的报告估计,消除ARHL可能与新发痴呆症减少8%有关。
至少与公认的风险因素一样多。然而,90%的目标人群没有接受治疗
助听器的有效性研究很少,也缺乏随机对照试验来测试助听器在ARHL中的疗效。虽然研究
建议助听器改善社会参与,大脑组织/连接,并反过来,认知,
没有RCT证据支持这些观察结果。有一项正在进行的RCT(ACHIEVE,ClinicalTrials.gov
NCT 03243422)检查听力干预对患有更高级认知障碍的老年人认知的影响。
阿尔。EARHLI专注于中老年早期ARHL,这是AD/ADRD预防的关键时期。
与ACHIEVE不同,EARHLI还测量大脑组织/连接。EARHLI将是一项II期1:1 RCT,
一项基于助听器的干预与对照(健康教育计划)进行了12个月,
150例有AD/ADRD风险的早期ARHL受试者(n=76例接受MRI)。总体假设是
听力干预将改善社会参与和大脑组织/连接,
与对照组相比,将导致认知改善。将对该假设进行检验,目的是-
比较听力干预组和对照组的治疗方法。目标1是比较
阿尔茨海默病临床前合作研究(Preclinical Alzheimer)
认知复合量表(ADCS-PACC; 1º结局)和ADCS-PACC领域特异性认知测试
组件(0、6、12个月)。目的2是比较通过活动衡量的社会参与的变化
参与(1º结果)和网络规模/支持(0、6、12个月)。目的3是比较大脑的变化
使用任务(视觉任务,听觉感兴趣区域,1º结果)和静息状态fMRI的组织/连接,
和扩散加权结构连接性(0、12个月)。我们将探讨社会参与和
脑组织/连接调节干预对认知结果的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Justin Scott Golub其他文献
AGE-RELATED HEARING LOSS AS A RISK FACTOR FOR LATE LIFE DEPRESSION AND COGNITIVE DECLINE: Session 408
- DOI:
10.1016/j.jagp.2019.01.195 - 发表时间:
2019-03-01 - 期刊:
- 影响因子:
- 作者:
Anu Sharma;Bret R Rutherford;Frank Lin;Justin Scott Golub;Katharine Kim Brewster - 通讯作者:
Katharine Kim Brewster
Justin Scott Golub的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Justin Scott Golub', 18)}}的其他基金
Early Age-Related Hearing Loss Investigation (EARHLI): A Randomized Controlled Trial to Assess Mechanisms Linking Early Age-Related Hearing Loss and Alzheimer's Disease and Related Dementias
早期年龄相关性听力损失调查 (EARHLI):一项随机对照试验,旨在评估早期年龄相关性听力损失与阿尔茨海默病和相关痴呆症之间的联系机制
- 批准号:
10703423 - 财政年份:2022
- 资助金额:
$ 107.67万 - 项目类别:
Mechanisms Linking Hearing Loss and Alzheimer's Disease and Related Dementias
听力损失与阿尔茨海默病及相关痴呆症的联系机制
- 批准号:
9895606 - 财政年份:2018
- 资助金额:
$ 107.67万 - 项目类别:
Mechanisms Linking Hearing Loss and Alzheimer's Disease and Related Dementias
听力损失与阿尔茨海默病及相关痴呆症的联系机制
- 批准号:
10396525 - 财政年份:2018
- 资助金额:
$ 107.67万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 107.67万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 107.67万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 107.67万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 107.67万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 107.67万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 107.67万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 107.67万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 107.67万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 107.67万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 107.67万 - 项目类别:
Fellowship Programs